Skip to main content
. 2025 Dec 8;64(2):57–65. doi: 10.5414/CP204781

Table 2. Parameter and covariate parameter estimates for the full population PK model.

Parameter estimates for the final full model
Estimate (RSE%) 95% CI for estimatea IIV (RSE%) 95% CI for IIVa
CL/F, L/hour 27.1 (2.41) 25.8, 28.5 28.2 (0.923) 21.4, 34.4
V/F, L 126 (2.81) 120, 134 36.6 (1.9) 25.6, 47.0
Ka/hour–1 3.07 (10.2) 2.56, 3.74 NA NA
Proportional error CV, TAD < 9 hours, % 60.2 (4.42) 54.8, 65.3 NA NA
Proportional error CV, TAD ≥ 9 hours, % 69.6 (6.73) 60.4, 78.3 NA NA
Covariance, CL/F-V/F 0.0760 (33.0) 0.0348, 0.131 NA NA
Covariate parameter estimates
PK parameter Covariate Estimateb (RSE%) 95% CIa
CL/F Age –0.244 (33.7) –0.419, –0.0989
CL/F Sex: Female (vs. male) 0.0237 (177) –0.0598, 0.107
CL/F Race: Asian (vs. non-Asian) –0.103 (31.7) –0.164, –0.0385
CL/F BCCL 0.233 (34.5) 0.0688, 0.377
CL/F BCRP –0.0185 (75.7) –0.0447, 0.00881
V/F Age –0.230 (42.3) –0.421, –0.0449
V/F Body weight 0.574 (23.1) 0.306, 0.835

BCCL = baseline creatinine clearance; BCRP = baseline C-reactive protein; CI = confidence interval; CL/F = apparent oral clearance; CV = coefficient of variation; IIV = inter-individual variance; Ka = first-order absorption rate constant; NA = not available; PK = pharmacokinetics; RSE = relative standard error; TAD = time after dose; V/F = apparent volume of distribution. The derived elimination half-life was ~ 3 hours. aPredicted by the bootstrap method. All 1,000 runs were minimized successfully. bFor continuous covariates, estimates were computed as power functions, normalized to the reference (approximate median) values in the dataset; for categorical covariates, estimates were computed as a fraction of the reference category, with one estimated coefficient for each category. Reference patient defined as: White, male, 78 kg, 40 years old, BCCL 126 mL/min, BCRP 0.851 mg/dL.